Here are the 10-Q quarterly reports from Protagenic Theraputcs WTS (PTIXW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTIXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTIXW filings page.
Protagenic Therapeutics, Inc. (PTIX) reported a sharp swing to quarterly net income of $2.21M for the three months ended December 31, 2025, driven mainly by a non‑cash gain of $3.11M from the change in fair value of derivative liabilities. Core operations remained loss‑making, with an operating loss of $0.93M in the quarter and $4.38M for the nine‑month period.
Total assets rose to $4.43M at December 31, 2025, primarily from acquiring Phytanix Bio’s in‑process R&D and assembled workforce recorded as intangible assets of $2.09M. Liabilities increased to $6.82M, leaving a stockholders’ deficit of $2.39M despite new equity, warrant exercises and non‑cash gains.
Cash used in operations was $3.07M over nine months, offset by $0.94M of net cash from the Phytanix Bio acquisition and $4.41M from financing activities, including $3.95M from warrant exercises and $0.40M from common stock sales, ending with cash of $2.21M.
The company disclosed a working capital deficit of $4.52M and an accumulated deficit of $9.11M as of December 31, 2025, and stated that recurring losses and expected funding needs within 12 months raise substantial doubt about its ability to continue as a going concern. Management highlighted a restructuring plan approved on August 8, 2025 to move to a virtual model and focus on priority clinical programs, targeting about $8M in annualized operating expense reductions. The report also details a reverse merger with Phytanix Bio completed in May 2025, recorded as a reverse acquisition, and notes that an agreement to rescind and unwind this merger was reached on February 17, 2026.